Last 719.15 INR
Change Today 0.00 / 0.00%
Volume 0.0
GNP On Other Exchanges
Natl India
As of 6:05 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

glenmark pharmaceuticals ltd (GNP) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/21/14 - 841.00
52 Week Low
05/19/14 - 507.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

glenmark pharmaceuticals ltd (GNP) Related Businessweek News

No Related Businessweek News Found

glenmark pharmaceuticals ltd (GNP) Details

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.

11,000 Employees
Last Reported Date: 07/1/14
Founded in 1977

glenmark pharmaceuticals ltd (GNP) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: 57.1M
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 16.3M
Director of Corporate Affairs, Executive Dire...
Total Annual Compensation: 18.3M
Compensation as of Fiscal Year 2014.

glenmark pharmaceuticals ltd (GNP) Key Developments

Glenmark Pharmaceuticals Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 03:00 PM

Glenmark Pharmaceuticals Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 03:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Glenn Mario Saldanha, Chairman of The Board, Chief Executive Officer, Managing Director, Member of Nomination and Remuneration Committee and Member of Shareholders/Investors Grievance Committee, Michael Buschle, Chief Scientific Officer.

Glenmark Pharmaceuticals Ltd. Announces Resignation of Hocine Sidi Said, Director

Glenmark Pharmaceuticals Ltd. announced that Mr. Hocine Sidi Said, Director of the Company has resigned from the Board with effect from November 25, 2014.

Glenmark Pharmaceuticals Announces Resignation of Hocine Sidi as Director

Glenmark Pharmaceuticals announced that Hocine Sidi, Director of the company has resigned from the Board with effect from November 25, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNP:IN 719.15 INR 0.00

GNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,638 INR -22.00
Impax Laboratories Inc $36.67 USD -1.02
Jubilant Life Sciences Ltd 172.70 INR -3.25
Lannett Co Inc $47.43 USD -2.68
Ranbaxy Laboratories Ltd 702.60 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation GNP Industry Range
Price/Earnings 31.9x
Price/Sales 3.0x
Price/Book -- Not Meaningful
Price/Cash Flow 22.6x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLENMARK PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at